Literature DB >> 25905599

Urinary podocalyxin, the novel biomarker for detecting early renal change in obesity.

Chayanut Suwanpen1, Phonethipsavanh Nouanthong2, Veeravich Jaruvongvanich3, Krit Pongpirul4,5, Wannarat Amornnimit Pongpirul6, Asada Leelahavanichkul7,8, Talerngsak Kanjanabuch9,10.   

Abstract

BACKGROUND: The prevalence of obesity is increasing during the past decade along with obesity-related glomerulopathy (ORG), glomeruli injury due to the obesity. The major pathogenesis of ORG is the shedding of podocytes from the glomerular cell barrier into urine. Podocalyxin (PCX), a main surface antigen of podocyte, correlates well with glomerulosclerosis progression and glomerular injury severity, and might be a potential biomarker for early renal alteration in obesity. In addition, vascular endothelial growth factor (VEGF) and alpha-smooth muscle actin (α-SMA) also play a role in promoting glomerulosclerosis. The aim of this study was to explore whether obese subjects without other diseases excrete more PCX-positive (PCX+) cells than non-obese individuals, in comparison with urine protein-creatinine ratio (UPCR) and glomerular filtration rate (GFR) as traditional renal markers. Moreover, the effect of body mass index (BMI) on urinary VEGF, PCX or α-SMA positive cells was also investigated.
METHODS: Forty-eight obese and 13 non-obese adults were included. Exfoliated cells from fresh first void morning urine were harvested, stained with PCX, VEGF, and α-SMA antibody, and quantified by flow cytometry. Correlation between interested urinary biomarkers (cells positive for PCX, VEGF plus PCX and α-SMA), UPCR and GFR with BMI and metabolic risk factors were analyzed.
RESULTS: Obese patients had significantly higher PCX+ cells than non-obese [0.62 (0.00-13.13) vs. 0.15 (0.00-0.72) cells/ml × mg cr, p < 0.05]. There was no significant difference in GFR and UPCR between the groups. Of interest, BMI demonstrated a correlation with PCX+ cells (r = 0.343, p = 0.008) and cells positive for PCX plus VEGF (r = 0.374, p = 0.004).
CONCLUSION: Obese subjects without other diseases and with normal UPCR and GFR showed evidence of renal alteration through the detection of a higher number of PCX+ cells. Increasing BMI also resulted in higher number of PCX+ cells.

Entities:  

Keywords:  Metabolic syndrome; Obesity; Podocalyxin; Podocyte; Proteinuria

Mesh:

Substances:

Year:  2015        PMID: 25905599     DOI: 10.1007/s40620-015-0199-8

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  31 in total

Review 1.  Myofibroblasts and mechano-regulation of connective tissue remodelling.

Authors:  James J Tomasek; Giulio Gabbiani; Boris Hinz; Christine Chaponnier; Robert A Brown
Journal:  Nat Rev Mol Cell Biol       Date:  2002-05       Impact factor: 94.444

2.  Ecscr regulates insulin sensitivity and predisposition to obesity by modulating endothelial cell functions.

Authors:  Yoshiki Akakabe; Masahiro Koide; Youhei Kitamura; Kiyonari Matsuo; Tomomi Ueyama; Satoaki Matoba; Hiroyuki Yamada; Keishi Miyata; Yuichi Oike; Koji Ikeda
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

3.  Myofibroblast phenotypes expression in experimental renal scarring.

Authors:  E C Muchaneta-Kubara; A M el Nahas
Journal:  Nephrol Dial Transplant       Date:  1997-05       Impact factor: 5.992

4.  Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples.

Authors:  S J Schwab; R L Christensen; K Dougherty; S Klahr
Journal:  Arch Intern Med       Date:  1987-05

5.  Urinary podocytes in primary focal segmental glomerulosclerosis.

Authors:  M Hara; T Yanagihara; I Kihara
Journal:  Nephron       Date:  2001-11       Impact factor: 2.847

Review 6.  Clinicopathological characteristics of obesity-associated focal segmental glomerulosclerosis.

Authors:  Sihem Darouich; Rym Goucha; Mohamed Habib Jaafoura; Semy Zekri; Hédi Ben Maiz; Adel Kheder
Journal:  Ultrastruct Pathol       Date:  2011-06-09       Impact factor: 1.094

7.  Urinary podocalyxin positive-element occurs in the early stage of diabetic nephropathy and is correlated with a clinical diagnosis of diabetic nephropathy.

Authors:  Hui Ye; Xueli Bai; Hua Gao; Li Li; Chunxiao Wu; Xinping Sun; Chunzhi Zhang; Yajuan Shen; Jian Zhang; Zhiming Lu
Journal:  J Diabetes Complications       Date:  2013-09-24       Impact factor: 2.852

Review 8.  Progenitor cells and podocyte regeneration.

Authors:  Stuart J Shankland; Jeffrey W Pippin; Jeremy S Duffield
Journal:  Semin Nephrol       Date:  2014-06-13       Impact factor: 5.299

9.  ELISA analysis of urinary nephrin and podocalyxin standardized by aquaporin-2 in adult patients with nephrotic syndrome.

Authors:  Bin Zhu; Xian-fa Li; Xiao-ling Zhu; Yi Lin; Sen Zhong; Cai-feng Zhu; Xuan-li Tang; Yun-qing Hu; Xiao-xia Cheng; Yong-jun Wang
Journal:  J Nephrol       Date:  2014-04-16       Impact factor: 3.902

10.  A novel method for the estimation of podocyte injury: podocalyxin-positive elements in urine.

Authors:  P Habara; H Marecková; Z Sopková; K Malícková; D Zivorová; T Zima; V Tesar
Journal:  Folia Biol (Praha)       Date:  2008       Impact factor: 0.906

View more
  3 in total

1.  Combination of cilostazol and probucol protected podocytes from lipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanisms.

Authors:  Peng He; Harukiyo Kawamura; Minoru Takemoto; Yoshiro Maezawa; Takahiro Ishikawa; Ryoichi Ishibashi; Kenichi Sakamoto; Mayumi Shoji; Akiko Hattori; Masaya Yamaga; Shintaro Ide; Kana Ide; Aiko Hayashi; Hirotake Tokuyama; Kazuki Kobayashi; Koutaro Yokote
Journal:  J Nephrol       Date:  2016-12-22       Impact factor: 3.902

Review 2.  Obesity-related glomerulopathy: Current approaches and future perspectives.

Authors:  José Ignacio Martínez-Montoro; Enrique Morales; Isabel Cornejo-Pareja; Francisco J Tinahones; José Carlos Fernández-García
Journal:  Obes Rev       Date:  2022-04-01       Impact factor: 10.867

3.  Radix Puerariae and Fructus Crataegi mixture inhibits renal injury in type 2 diabetes via decreasing of AKT/PI3K.

Authors:  Zhengyue Chen; Yanyan Yuan; Xinrong Zou; Mengqi Hong; Ming Zhao; Yu Zhao; Yuanping Liu; Guofu Li; Yabin Zhu; Lin Luo; Beiyan Bao; Shizhong Bu
Journal:  BMC Complement Altern Med       Date:  2017-09-08       Impact factor: 3.659

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.